Tau Expression and Docetaxel Sensitivity in Tumors
Author Information
Author(s): R Veitia, M-C Bissery, C Martinez, A Fellous
Primary Institution: Institut Pasteur
Hypothesis
Can the expression levels of Tau and microtubule components explain the sensitivity of tumors to docetaxel?
Conclusion
Higher levels of Tau isoforms in docetaxel-sensitive tumors may serve as markers for drug sensitivity.
Supporting Evidence
- Docetaxel was found to be active on three out of four mammary tumors and one out of two pancreatic tumors.
- Sensitive tumors showed higher levels of Tau mRNA compared to refractory tumors.
- Complete tumor regressions were observed in several sensitive tumor models after docetaxel treatment.
Takeaway
This study looked at how certain proteins in tumors affect their response to a cancer drug called docetaxel, finding that more of a protein called Tau means the tumors are more likely to respond to the drug.
Methodology
The study used RT-PCR and Western blot analysis to assess the expression of microtubule-associated proteins and tubulin isoforms in various tumor models.
Limitations
The study primarily focused on murine models, which may not fully represent human tumor behavior.
Participant Demographics
The study involved various murine tumor models, including mammary and pancreatic adenocarcinomas.
Want to read the original?
Access the complete publication on the publisher's website